vTv Therapeutics (VTVT) Q1 2025 earnings summary

Executive summary

• Focused on therapies for metabolic and inflammatory diseases, with lead candidate cadisegliatin for type 1 diabetes in Phase 3 development and additional pipeline assets in earlier stages.

• Reinitiated screening for the Phase 3 CATT1 trial of cadisegliatin, with topline data expected in the second half of 2026 after a protocol amendment shortened study duration from 12 to 6 months.

• Cadisegliatin aims to be the first oral adjunctive therapy to insulin for T1D, with continuous glucose monitors now provided to trial participants.

• No product revenue to date; revenue is derived from milestone and license payments under collaboration agreements.

• FDA clinical hold on cadisegliatin was lifted in March 2025, allowing resumption of the CATT1 trial.

Financial highlights

• Net loss attributable to common shareholders was $5.1 million ($0.77 per share) for Q1 2025, compared to $4.9 million ($1.17 per share) in Q1 2024.

• Cash and cash equivalents were $31.1 million as of March 31, 2025, down from $36.7 million at December 31, 2024.

• Research and development expenses increased to $2.8 million from $2.6 million year-over-year, while general and administrative expenses decreased to $3.7 million from $4.0 million.

• No revenue recognized in Q1 2025; $1.0 million revenue in Q1 2024 from a milestone under the Newsoara License Agreement.

• Operating loss for Q1 2025 was $6.5 million, compared to $6.6 million in Q1 2024.

Outlook and guidance

• Expects continued losses and negative cash flow from operations as clinical trials progress.

• Additional capital will be required to fund ongoing and future operations; evaluating equity investments and licensing opportunities.

• Topline data from the CATT1 study for cadisegliatin expected in the second half of 2026, with two international registrational studies planned for 2027.

• No guarantee of regulatory approval or commercial availability for cadisegliatin.